Georgia Tech Research Corporation

John Francis McDonald

Facundo Martin Fernandez

Louis Andrew Lyon

LiJuan Wang

Erin Beth Dickerson

David Gaul

Nathan John Bowen

William Hobart Blackburn

A method of detecting serous ovarian cancer, particularly early stage serous ovarian cancer is described. The method uses up to sixteen compounds found in the blood serum of a person, and determines that changes of some portion of these sixteen compounds can determine the presence of serous ovarian cancer in a women with up to 100% accuracy, specificity, and sensitivity.

Detection and treatment of of early-stage ovarian cancer

The present invention provides a method of treating an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to treat the ovarian cancer. Also provided are methods of preventing metastasis of an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to prevent metastasis. Further provided are methods of sensitizing an ovarian cancer to a cytotoxic therapy, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to sensitize the ovarian cancer to the cytotoxic therapy. The invention also contemplates methods of reducing epithelial-to-mesenchymal transition (EMT) in an ovarian cancer or cancer cell as well as methods of inducing mesenchymal-to-epithelial transition (MET).

MIR-200 family induces mesenchymal-to-epithelial transition (MET) in ovarian cancer cells

The various embodiments of the present disclosure relate generally to nanogels for the cellular delivery of therapeutics and methods of using the same. More particularly, the various embodiments of the present invention are directed to systems and methods for the targeted treatment of neoplastic using nanogel-based technologies. In an embodiment of the present invention, a nanogel-based delivery system comprises: a nanogel comprising a crosslinked polymer particle; and an active agent contained substantially within the nanogel, wherein the active agent is non-covalently associated with the nanogel.

Nanogels for cellular delivery of therapeutics

Growing community of inventors

Arnoldsville, GA, United States of America

John Francis McDonald